- Spyre Therapeutics (SYRE, Financial) to host a conference call and webcast on June 17, 2025, to discuss Phase 1 interim results for SPY002.
- SPY002 program focuses on novel half-life extended anti-TL1A antibodies for treating Inflammatory Bowel Disease and other immune-mediated diseases.
- The webcast can be accessed via Spyre's Investor Relations webpage, with an archived version available for a limited time.
Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company, announced that it will report interim results from its Phase 1 clinical trials of the SPY002 program on June 17, 2025. The trials involve healthy volunteers and focus on novel half-life extended anti-TL1A antibodies aimed at treating Inflammatory Bowel Disease (IBD) and other immune-mediated diseases.
The company will hold a conference call and webcast at 8:00am ET on the same day to discuss these interim results. Interested parties can attend the live presentation or access a recorded version, which will be available for a limited time on the company’s Investor Relations webpage at https://ir.spyre.com/events-and-presentations.
Spyre Therapeutics is dedicated to advancing best-in-class antibody engineering and therapeutic combinations. Its SPY002 program is a part of a broader pipeline aimed at developing next-generation products for inflammatory and immune-mediated diseases. For further details about Spyre Therapeutics and its initiatives, visit their official website at http://spyre.com.
